BioPharmSignal logoBioPharmSignal

Biotech News

Sarepta Therapeutics to Present at the Morgan Stanley 24th Annual Global Healthcare Conference

Sarepta Therapeutics (SRPT)Sarepta TherapeuticsConference / presentation

CAMBRIDGE, Mass. --(BUSINESS WIRE)--Aug. 31, 2026-- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced that senior management will participate in a fireside chat at the Morgan Stanley 24 th Annual Global Healthcare Conference on

Related news

SRPTSarepta Therapeutics2026-05-13 20:30 EST

Sarepta Therapeutics to Present at the RBC Capital Markets Global Healthcare Conference

CRSPCRISPR Therapeutics2026-09-08 12:30 EST

CRISPR Therapeutics to Present at the Morgan Stanley 24th Annual Global Healthcare Conference

NTLAIntellia2026-09-04 12:00 EST

Intellia Therapeutics to Present at Morgan Stanley 24th Annual Global Healthcare Conference

CRSPCRISPR Therapeutics2026-05-06 12:30 EST

CRISPR Therapeutics to Present at the Bank of America Securities 2026 Global Healthcare Conference

SANASana Biotechnology2026-05-05 20:05 EST

Sana Biotechnology to Present at the BofA Securities 2026 Healthcare Conference

KRYSKrystal Biotech2026-09-03 12:00 EST

Krystal Biotech to Present at 2026 Cantor Global Healthcare Conference

SRPTSarepta Therapeutics2026-09-08 13:00 EST

Sarepta Therapeutics Announces Recipients of Route 79, The Duchenne Scholarship Program, for the 2026-2027 Academic Year

CRBUCaribou2026-05-27 20:05 EST

Caribou Biosciences to Participate in the 2026 Jefferies Global Healthcare Conference

PHARPharming Group2026-06-02 06:00 EST

Pharming Group to participate in Fireside Chat at 2026 Jefferies Global Healthcare Conference in New York

SANASana Biotechnology2026-09-01 20:05 EST

Sana Biotechnology to Present at September 2026 Investor Conferences

View all latest news

Sarepta Therapeutics

Precision Genetic Medicine Sarepta Therapeutics develops and commercializes genetic medicines for rare neuromuscular diseases, with a major focus on Duchenne muscular dystrophy. ELEVIDYS ELEVIDYS is an AAV-based gene-transfer therapy that delivers a micro-dystrophin transgene to skeletal muscle. It is indicated for ambulatory patients...

Recent company news

SRPTSarepta Therapeutics2026-09-08 13:00 EST

Sarepta Therapeutics Announces Recipients of Route 79, The Duchenne Scholarship Program, for the 2026-2027 Academic Year

SRPTSarepta Therapeutics2026-09-08 12:59 EST

Sarepta Therapeutics anuncia a los destinatarios de Route 79, el Programa de Becas de Duchenne, para el año académico 2026-2027

SRPTSarepta Therapeutics2026-08-31 20:30 EST

Sarepta Therapeutics to Present at the Morgan Stanley 24th Annual Global Healthcare Conference

SRPTSarepta Therapeutics2026-08-05 20:05 EST

Sarepta Therapeutics Announces Second Quarter 2026 Financial Results and Recent Corporate Developments

SRPTSarepta Therapeutics2026-07-29 21:00 EST

Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Stock data

Close
20.67 USD
Market cap
1.72B USD
Exchange
NASDAQ
Sector
Gene Therapy
Location
United States